<DOC>
	<DOCNO>NCT02887183</DOCNO>
	<brief_summary>This study determine early chronic change concentration biomarkers related mechanism action ( MOA ) effect sacubitril/valsartan therapyover period 12 month , correlate biomarker change cardiac remodel parameter , patient-reported outcome cardiovascular outcome .</brief_summary>
	<brief_title>Effects Sacubitril/Valsartan Therapy Biomarkers , Myocardial Remodeling Outcomes .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Based USPI sacubitril/valsartan , subject eligible inclusion study must fulfill follow criterion screen baseline : 1 . Written informed consent must obtain assessment perform . 2 . Men woman ≥ 18 year age . 3 . HFrEF ≤ 40 % subject candidate onlabel sacubitril/valsartan treatment per standard care . 4 . New York Heart Association ( NYHA ) Functional class IIIV . 5 . LVEF ≤40 % via local measurement within past 6 month use echocardiography , multi gated acquisition scan ( MUGA ) , CT scanning , MRI ventricular angiography provide subsequent study document EF &gt; 40 % . If EF measurement express value range , average range endpoint value use EF . 6 . Stable loop diuretic dose 2 week baseline . Key Subjects fulfil follow criterion , screen prior dispense study drug , eligible inclusion study . No additional exclusion may apply investigator , order ensure study population representative eligible subjects/subjects . 1 . History hypersensitivity study drug , include history hypersensitivity drug similar chemical class , allergy angiotensin convert enzyme inhibitor ( ACEIs ) , Angiotensin II Receptor Blockers ( ARBs ) , Neutral endopeptidase ( NEP ) inhibitor well know suspect contraindication study drug . 2 . History angioedema drug relate otherwise . 3 . Concomitant use ACEI . 4 . Current prior treatment sacubitril/valsartan . 5 . Subjects take medication prohibit protocol . 6 . Subjects diabetes mellitus take aliskiren . 7 . Use investigational drug within 5 halflives enrollment , within 30 day expect pharmacodynamic effect return baseline , whichever longer . 8 . Concomitant use nesiritide . 9 . Bile acid sequester agent cholestyramine colestipol prohibit avoid interference study drug absorption . 10 . Hospital discharge use outpatient i.v . diuretic therapy within 2 week prior enrollment . 11 . Enrollment another clinical trial within 30 day screen . 12 . Potassium &gt; 5.2 mEq/L screening . 13 . History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within one year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Reduced leave ventricular ejection fraction</keyword>
	<keyword>HFrEF</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>Cardiac remodeling</keyword>
</DOC>